Clinical Outcome in Uveitis

Uveitis Clinical Trial

Official title:

Clinical Outcome and Causes of Visual Loss in Uveitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01983488
• Other study ID #: LIGS10201
• Status: Completed
• Start date: September 2011
• Est. completion date: December 1, 2019

Study information

• Verified date: February 2021
• Source: Moorfields Eye Hospital NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is aimed at investigating the long term clinical outcome of patients with uveitis.

Description:

Patients will be included if they are treated for uveitis and have had repeat follow-up. Data will be gathered from the entire length of the patients follow-up. The main outcome measures will be: Change from baseline of Best corrected visual acuity (BCVA)at 10 years Causes of vision loss (≤6/15, VL) and severe vision loss (≤6/60, SVL) at 10 years Number of clinical visits at 10 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 231
• Est. completion date: December 1, 2019
• Est. primary completion date: December 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Clinical Diagnosis of Uveitis.

Exclusion Criteria:

• No follow-up data.

Related Conditions & MeSH terms

• Uveitis

Locations

Country	Name	City	State
United Kingdom	Moorfields Eye Hospital	London

Sponsors (1)

Lead Sponsor	Collaborator
Moorfields Eye Hospital NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

References & Publications (2)

Bodaghi B, Cassoux N, Wechsler B, Hannouche D, Fardeau C, Papo T, Huong DL, Piette JC, LeHoang P. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore). 2001 Jul;80(4):263-70. — View Citation

Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996 Apr;80(4):332-6. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best Corrected Visual Acuity	Recorded repeat best corrected visual acuity at intervals throughout the length of follow-up.	up to 10 years
Secondary	Causes of visual loss	Record any ocular changes related to permanent visual loss under 6/12 and severe visual loss under 6/60.	First follow-up, years 1,2,5,10, Final follow-up